Rabeprazole sodium and Pulmonary function test decreased - a phase IV clinical study of FDA data

Summary:

Pulmonary function test decreased is reported as a side effect among people who take Rabeprazole sodium (rabeprazole sodium), especially for people who are female, 50-59 old, also take Prednisone, and have Systemic sclerosis (scleroderma).

The phase IV clinical study analyzes which people have Pulmonary function test decreased when taking Rabeprazole sodium. It is created by eHealthMe based on reports of 15,623 people who have side effects when taking Rabeprazole sodium from the FDA, and is updated regularly.

What is Rabeprazole sodium?

Rabeprazole sodium has active ingredients of rabeprazole sodium. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 15,786 Rabeprazole sodium users. Check the latest studies of Rabeprazole sodium.

What is Pulmonary function test decreased?

Pulmonary function test decreased is found to be associated with 469 drugs and 497 conditions by eHealthMe. Check the latest studies of Pulmonary function test decreased.

On Jul, 18, 2026

15,623 people reported to have side effects when taking Rabeprazole sodium.
Among them, 18 people (0.12%) have Pulmonary function test decreased.

Could Rabeprazole sodium cause Pulmonary function test decreased?

Among these 18 people:

What is the gender of people who have Pulmonary function test decreased when taking Rabeprazole sodium? *

female: 80 %
male: 20 %

What is the age of people who have Pulmonary function test decreased when taking Rabeprazole sodium? *

What are other drugs people take besides Rabeprazole sodium? *

What are other side effects people have besides Pulmonary function test decreased? *

Cough: 12 people, 66.67%
Laryngitis (inflammation of the larynx): 9 people, 50.00%
Lung Neoplasm Malignant (cancer tumour of lung): 9 people, 50.00%
Hypoaesthesia (reduced sense of touch or sensation): 9 people, 50.00%
Fatigue (feeling of tiredness): 8 people, 44.44%
Stress And Anxiety: 8 people, 44.44%
Anaemia (lack of blood): 5 people, 27.78%
Hiatal Hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm): 4 people, 22.22%
Skin Exfoliation (removal of the oldest dead skin cells): 3 people, 16.67%
Respiratory Distress (difficulty in breathing): 3 people, 16.67%

What are the existing conditions these people have? *

Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 9 people, 50.00%
Interstitial Lung Disease: 7 people, 38.89%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 5 people, 27.78%
Myasthenia Gravis (a chronic condition that causes muscles to tire and weaken easily): 3 people, 16.67%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Rabeprazole sodium and have Pulmonary function test decreased?

- Check whether Pulmonary function test decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rabeprazole sodium:

Rabeprazole sodium (15,786 reports)

Browse all side effects of Rabeprazole sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary function test decreased:

Pulmonary function test decreased (469 drugs)

Browse all the conditions that are associated with Pulmonary function test decreased:

Pulmonary function test decreased (497 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rabeprazole sodium (the active ingredients of Rabeprazole sodium) and Rabeprazole sodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.